Developer docs
API playgroundTry for free, no card

Search company profiles

CB Therapeutics

Full company profile

uuid0002egw

Namestring
CB Therapeutics
Legal namestring
CB Therapeutics Inc.
Websiteurl
cbthera.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

CB Therapeutics is a precision fermentation biotech company founded in 2018 by Sher Butt (CEO) and Jacob Vogan (CSO), operating a 16,000 sq ft biomanufacturing facility in Carlsbad, California. The company engineers yeast strains to biosynthetically produce more than 100 rare compounds across eight classes, including phytocannabinoids, tryptamines, rare alkaloids, terpenes, peptides, and designed analogs, running an integrated platform from bioprospecting through strain engineering, fermentation, and downstream processing. The platform follows a closed-loop Design-Build-Test-Learn cycle underpinned by the proprietary TryptageniX AI data layer, and the company holds eight granted US patents spanning yeast strains, biosynthetic pathways, downstream chemistry, enzyme and gene mining, and bioinformatics methods.

The product surface is organized around four branded programs: TryptageniX (rare alkaloid research for mental-health therapeutics), TryptageniX AI (data and agentic-AI platform for biological design), Aevora (yeast-derived peptide extracts for healthspan, vitality, hair, skin, and metabolic health), and Korvane (non-opioid pain research featuring minor-kratom alkaloid blends with liposomal delivery). The company generates revenue through B2B sales of research-grade and pharmaceutical-grade compounds, research collaborations, and licensing of proprietary biosynthesis pathways. Customers are concentrated in pharma companies, biotech firms, and research institutions developing psychedelic-inspired, tryptamine-based, and pain therapeutics, with named engagements including Cleveland Clinic (2020 MOU for psilocybin, DMT, MDMA research samples) and an unnamed Colorado research client receiving the first research-supply delivery in June 2020. Distribution is exclusively through direct B2B partnership outreach with no self-serve or consumer channel.

Short descriptiontext

CB Therapeutics is a precision fermentation biotech that engineers yeast to biosynthetically produce rare compounds (cannabinoids, tryptamines, alkaloids, peptides) for pharmaceutical, biotech, and research customers. Operating from a 16,000 sq ft Carlsbad facility with eight US patents, it sells research-grade compounds and licenses platform IP.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCarlsbad, United States
HQ citystring
Carlsbad
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
precision fermentation, biosynthetic cannabinoids, yeast strain engineering, alkaloid biosynthesis, AI-guided biomanufacturing
Industry3 codes
PRIMARYCRADAGAD
Herbal & Botanical Supplements
SECONDARYHLAIADAG
Sleep, Stress & Mood Support
Healthcare & Life Sciences/Pharmaceuticals/Over-the-Counter (OTC) Medicines
SECONDARYHLAGAHAD
Controlled Substances / DEA-Scheduled API Manufacturing
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
NAICS code3 codes
  • Medicinal and Botanical Manufacturing325411
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical and Medicine Manufacturing32541
SIC code2 codes
  • Medicinal Chemicals & Botanical Products2833
  • Pharmaceutical Preparations2834
Product category
Biopharmaceutical Manufacturing
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Biosynthetic Compound Sales
TypeOne Time License
Description

Sale of research-grade and pharmaceutical-grade compounds produced via precision fermentation. Compounds sold to research institutions, pharma companies, and wellness companies for mental health research, therapeutics development, and consumer product formulation.

cbthera.com
2Research Collaborations & Licensing
TypeLicensing Royalties
Description

Collaborative research arrangements with pharmaceutical partners, research institutions, and formulation companies. Includes licensing of proprietary biosynthesis pathways and co-development partnerships.

cbthera.com
3Platform Technology Access
TypeProfessional Services
Description

Partnership-based access to the fermentation platform for specific compound classes, enzyme engineering services, and strain development for external partners.

cbthera.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Infrastructure, Operations, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1TryptageniX
Description

Rare alkaloid research program covering MIA pathway, mitragynine, ergolines, and salvinorins for mental health applications.

cbthera.com
+3 more records
Core offering1 text field

CB Therapeutics operates a precision fermentation platform that uses engineered yeast strains to biosynthetically produce over 100 rare compounds across eight classes, including phytocannabinoids (CBD, CBG, CBC, CBN, THCV), tryptamines (psilocybin, DMT, baeocystin, 5-HTP), rare alkaloids (mitragynine, stemmadenine acetate, catharanthine, tabersonine, salvinorin A), terpenes, ergolines, peptides, and designed analogs. The company supplies research-grade and pharmaceutical-grade compounds to pharmaceutical, biotech, research, wellness, and food-tech customers through direct B2B partnerships, research collaborations, and licensing agreements, with four branded programs—TryptageniX, TryptageniX AI, Aevora, and Korvane—covering mental health, AI-guided biological design, healthspan peptides, and non-opioid pain research.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 99.6% purity achieved on rare cannabinoids (CBC benchmark, 2021)
+2 more records
Product overview1 text field

CB Therapeutics operates a unified precision fermentation platform with four branded programs. The core platform uses engineered yeast strains to biosynthetically produce rare compounds across eight classes: phytocannabinoids, cannabinoid analogs, terpenes, tryptamines, tryptamine analogs, rare alkaloids, food-tech compounds, and novel food additives. Four programs build on this platform: TryptageniX (rare alkaloid research for mental health), TryptageniX AI (AI-guided data platform for agentic biological design), Aevora (peptide-enriched extracts for healthspan), and Korvane (minor keto alkaloid blend for non-opioid pain research). The platform has achieved 99.6% purity benchmarks and holds 8 granted US patents.

Product and service5 records
1Precision Fermentation Platform
CategoryCore Biomanufacturing Platform
Description

A yeast-based precision fermentation platform that biosynthetically produces over 100 rare compounds including phytocannabinoids, tryptamines, ergolines, alkaloids, peptides, and terpenes for pharmaceutical, biotech, research, wellness, and food-tech customers.

2TryptageniX
CategoryMental Health Research Program
Description

A rare alkaloid research program developing fermentation routes for natural products limited by scarce source material. Covers MIA pathway intermediates (stemmadenine acetate, tabersonine, catharanthine), kratom alkaloids (mitragynine), ergolines (agroclavine), and salvinorins for mental health research and therapeutics.

3TryptageniX AI
CategoryAI Data Platform
Description

The data and AI platform behind CBT's fermentation platform that converts wet-lab cycles into training signal for agentic AI. Captures strain designs, fermentation outcomes, sample analysis, and structured data to sharpen biological design decisions.

4Aevora
CategoryHealthspan & Functional Ingredients Program
Description

A peptide-enriched yeasted extract program for healthspan applications including vitality, hair and skin health, metabolic rhythm, and body composition. Produced through precision fermentation in yeast without animal-source material.

5Korvane
CategoryNon-Opioid Pain Research Program
Description

A non-opioid pain research program featuring a precision blend of minor kratom alkaloids (paynantheine, speciociliatine, and proprietary lead alkaloid) produced via yeast fermentation and formulated for liposomal delivery. Targets chronic pain without the dominant alkaloids carrying opioid-like risk.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-04-01
Description

MOU signed to provide research-use samples of psilocybin, DMT, and MDMA to Cleveland Clinic for depression, addiction, and PTSD studies. Validates platform's ability to produce clinical-grade compounds for medical research.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Largest publicly listed precision fermentation / cell engineering platform; offers strain engineering, fermentation, and downstream services across many of the same end-markets (food ingredients, flavors, cannabinoids, therapeutics). Directly comparable as a multi-vertical fermentation platform with code-driven strain design.

TypeDirect peer
Description

Fermentation-derived specialty ingredients company that produced cannabinoids (e.g., CBG), terpenes, and flavor/fragrance molecules from engineered yeast at commercial scale. Closely comparable business model of using precision fermentation to serve wellness, flavor, and consumer product markets.

TypeDirect peer
Description

Precision fermentation company producing rare and sustainable ingredients via engineered microbes, including cannabinoids, flavors, fragrances, and nutritional compounds. Closely comparable in scale, technology stack, and target customer segments.

TypeDirect peer
Description

Biotech using precision fermentation to produce novel oils, polyols, and ingredients for personal care, food, and materials. Comparable as a fermentation platform commercializing novel compounds via B2B partnerships with consumer-facing brands.

TypeDirect peer
Description

Clinical-stage biotech using engineered spirulina/yeast-based precision fermentation to manufacture biologics, peptides, and therapeutic proteins at scale. Comparable in combining fermentation manufacturing with pharma-style therapeutic development for rare compounds.

TypeBroad incumbent
Description

Public enzyme-engineering and biocatalysis company serving pharmaceutical, food, and industrial customers. Overlapping in enzyme and pathway engineering IP for small-molecule and biological manufacturing, though Codexis is more established and broader in scope.

TypeDirect peer
Description

Precision fermentation company producing microbial nitrogen-fixing and crop nutrition products for agriculture. Comparable as a venture-backed fermentation platform company that has successfully commercialized engineered-microbe products in a regulated B2B market.

TypeEmerging player
Description

Clinical-stage mental health company developing psilocybin therapy for treatment-resistant depression. Comparable end-market focus on psychedelic-derived mental-health therapeutics; differs in using chemical synthesis rather than biosynthesis for its COMP360 psilocybin.

9ATAI Life Sciences
TypeOthers
Description

Clinical-stage biopharma platform developing psychedelic and mental-health therapeutics. Listed in CBT's materials as a joint venture partner on TryptageniX (ATAI relationship) and represents both a comparable psychedelic therapeutics peer and a financial/strategic partner.

TypeDirect peer
Description

Industrial biotechnology / contract research organization offering precision fermentation, strain engineering, and bioprocess development services to pharma and specialty chemical clients. Comparable as a service-and-platform provider of microbial production for rare and high-value compounds.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

CB Therapeutics

Biopharmaceutical Manufacturingcbthera.com

CB Therapeutics is a precision fermentation biotech that engineers yeast to biosynthetically produce rare compounds (cannabinoids, tryptamines, alkaloids, peptides) for pharmaceutical, biotech, and research customers. Operating from a 16,000 sq ft Carlsbad facility with eight US patents, it sells research-grade compounds and licenses platform IP.

What CB Therapeutics does

CB Therapeutics is a precision fermentation biotech company founded in 2018 by Sher Butt (CEO) and Jacob Vogan (CSO), operating a 16,000 sq ft biomanufacturing facility in Carlsbad, California. The company engineers yeast strains to biosynthetically produce more than 100 rare compounds across eight classes, including phytocannabinoids, tryptamines, rare alkaloids, terpenes, peptides, and designed analogs, running an integrated platform from bioprospecting through strain engineering, fermentation, and downstream processing. The platform follows a closed-loop Design-Build-Test-Learn cycle underpinned by the proprietary TryptageniX AI data layer, and the company holds eight granted US patents spanning yeast strains, biosynthetic pathways, downstream chemistry, enzyme and gene mining, and bioinformatics methods.

The product surface is organized around four branded programs: TryptageniX (rare alkaloid research for mental-health therapeutics), TryptageniX AI (data and agentic-AI platform for biological design), Aevora (yeast-derived peptide extracts for healthspan, vitality, hair, skin, and metabolic health), and Korvane (non-opioid pain research featuring minor-kratom alkaloid blends with liposomal delivery). The company generates revenue through B2B sales of research-grade and pharmaceutical-grade compounds, research collaborations, and licensing of proprietary biosynthesis pathways. Customers are concentrated in pharma companies, biotech firms, and research institutions developing psychedelic-inspired, tryptamine-based, and pain therapeutics, with named engagements including Cleveland Clinic (2020 MOU for psilocybin, DMT, MDMA research samples) and an unnamed Colorado research client receiving the first research-supply delivery in June 2020. Distribution is exclusively through direct B2B partnership outreach with no self-serve or consumer channel.

CB Therapeutics firmographics

Firmographics
Name
CB Therapeutics
Legal name
CB Therapeutics Inc.
Website
https://cbthera.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
CB Therapeutics is a precision fermentation biotech that engineers yeast to biosynthetically produce rare compounds (cannabinoids, tryptamines, alkaloids, peptides) for pharmaceutical, biotech, and research customers. Operating from a 16,000 sq ft Carlsbad facility with eight US patents, it sells research-grade compounds and licenses platform IP.
Ownership category
akta.pro rank

CB Therapeutics industry classification

Industry
Product category
Biopharmaceutical Manufacturing
NAICS
Medicinal and Botanical Manufacturing (325411), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (32541)
SIC
Medicinal Chemicals & Botanical Products (2833), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYCRADAGAD
Herbal & Botanical Supplements
SECONDARYHLAIADAG
Sleep, Stress & Mood Support
Healthcare & Life Sciences/Pharmaceuticals/Over-the-Counter (OTC) Medicines
SECONDARYHLAGAHAD
Controlled Substances / DEA-Scheduled API Manufacturing
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services

Keywords

  • Precision fermentation
  • Biosynthetic cannabinoids
  • Yeast strain engineering
  • Alkaloid biosynthesis
  • AI-guided biomanufacturing

Where CB Therapeutics is headquartered

Location

Headquarters

HQ city
Carlsbad
HQ country
United States
HQ region
North America

Offices1 record

Markets served

CB Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Infrastructure, Operations, Supply Chain

Revenue model

  1. Biosynthetic Compound Sales: Sale of research-grade and pharmaceutical-grade compounds produced via precision fermentation. Compounds sold to research institutions, pharma companies, and wellness companies for mental health research, therapeutics development, and consumer product formulation.
  2. Research Collaborations & Licensing: Collaborative research arrangements with pharmaceutical partners, research institutions, and formulation companies. Includes licensing of proprietary biosynthesis pathways and co-development partnerships.
  3. Platform Technology Access: Partnership-based access to the fermentation platform for specific compound classes, enzyme engineering services, and strain development for external partners.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

CB Therapeutics product offering

Product offering

Core offering

CB Therapeutics operates a precision fermentation platform that uses engineered yeast strains to biosynthetically produce over 100 rare compounds across eight classes, including phytocannabinoids (CBD, CBG, CBC, CBN, THCV), tryptamines (psilocybin, DMT, baeocystin, 5-HTP), rare alkaloids (mitragynine, stemmadenine acetate, catharanthine, tabersonine, salvinorin A), terpenes, ergolines, peptides, and designed analogs. The company supplies research-grade and pharmaceutical-grade compounds to pharmaceutical, biotech, research, wellness, and food-tech customers through direct B2B partnerships, research collaborations, and licensing agreements, with four branded programs—TryptageniX, TryptageniX AI, Aevora, and Korvane—covering mental health, AI-guided biological design, healthspan peptides, and non-opioid pain research.

Product overview

CB Therapeutics operates a unified precision fermentation platform with four branded programs. The core platform uses engineered yeast strains to biosynthetically produce rare compounds across eight classes: phytocannabinoids, cannabinoid analogs, terpenes, tryptamines, tryptamine analogs, rare alkaloids, food-tech compounds, and novel food additives. Four programs build on this platform: TryptageniX (rare alkaloid research for mental health), TryptageniX AI (AI-guided data platform for agentic biological design), Aevora (peptide-enriched extracts for healthspan), and Korvane (minor keto alkaloid blend for non-opioid pain research). The platform has achieved 99.6% purity benchmarks and holds 8 granted US patents.

Differentiator

Problem solved

Functional benefit

Brands

  • TryptageniX: Rare alkaloid research program covering MIA pathway, mitragynine, ergolines, and salvinorins for mental health applications.
  • TryptageniX AI
  • Aevora
  • Korvane

Products and services

  • Precision Fermentation Platform A yeast-based precision fermentation platform that biosynthetically produces over 100 rare compounds including phytocannabinoids, tryptamines, ergolines, alkaloids, peptides, and terpenes for pharmaceutical, biotech, research, wellness, and food-tech customers.
  • TryptageniX A rare alkaloid research program developing fermentation routes for natural products limited by scarce source material. Covers MIA pathway intermediates (stemmadenine acetate, tabersonine, catharanthine), kratom alkaloids (mitragynine), ergolines (agroclavine), and salvinorins for mental health research and therapeutics.
  • TryptageniX AI The data and AI platform behind CBT's fermentation platform that converts wet-lab cycles into training signal for agentic AI. Captures strain designs, fermentation outcomes, sample analysis, and structured data to sharpen biological design decisions.
  • Aevora A peptide-enriched yeasted extract program for healthspan applications including vitality, hair and skin health, metabolic rhythm, and body composition. Produced through precision fermentation in yeast without animal-source material.
  • Korvane A non-opioid pain research program featuring a precision blend of minor kratom alkaloids (paynantheine, speciociliatine, and proprietary lead alkaloid) produced via yeast fermentation and formulated for liposomal delivery. Targets chronic pain without the dominant alkaloids carrying opioid-like risk.

Quantifiable outcome

  • 99.6% purity achieved on rare cannabinoids (CBC benchmark, 2021)
  • +2 more outcomes

Companies that use CB Therapeutics

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles5 records

CB Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature5 records

CB Therapeutics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Cleveland CliniccoreStrategic or Co-development Partner · 1 April 2020MOU signed to provide research-use samples of psilocybin, DMT, and MDMA to Cleveland Clinic for depression, addiction, and PTSD studies. Validates platform's ability to produce clinical-grade compounds for medical research.

Scale indicators7 records

Recent moves8 records

Expansion highlights6 records

CB Therapeutics competitors and assessment

Company assessment

Direct peers

  • Ginkgo Bioworks: Largest publicly listed precision fermentation / cell engineering platform; offers strain engineering, fermentation, and downstream services across many of the same end-markets (food ingredients, flavors, cannabinoids, therapeutics). Directly comparable as a multi-vertical fermentation platform with code-driven strain design.
  • Amyris: Fermentation-derived specialty ingredients company that produced cannabinoids (e.g., CBG), terpenes, and flavor/fragrance molecules from engineered yeast at commercial scale. Closely comparable business model of using precision fermentation to serve wellness, flavor, and consumer product markets.
  • Conagen: Precision fermentation company producing rare and sustainable ingredients via engineered microbes, including cannabinoids, flavors, fragrances, and nutritional compounds. Closely comparable in scale, technology stack, and target customer segments.
  • Checkerspot: Biotech using precision fermentation to produce novel oils, polyols, and ingredients for personal care, food, and materials. Comparable as a fermentation platform commercializing novel compounds via B2B partnerships with consumer-facing brands.
  • Lumen Bioscience: Clinical-stage biotech using engineered spirulina/yeast-based precision fermentation to manufacture biologics, peptides, and therapeutic proteins at scale. Comparable in combining fermentation manufacturing with pharma-style therapeutic development for rare compounds.
  • Pivot Bio: Precision fermentation company producing microbial nitrogen-fixing and crop nutrition products for agriculture. Comparable as a venture-backed fermentation platform company that has successfully commercialized engineered-microbe products in a regulated B2B market.
  • Ingenza: Industrial biotechnology / contract research organization offering precision fermentation, strain engineering, and bioprocess development services to pharma and specialty chemical clients. Comparable as a service-and-platform provider of microbial production for rare and high-value compounds.

Broad incumbents

  • Codexis: Public enzyme-engineering and biocatalysis company serving pharmaceutical, food, and industrial customers. Overlapping in enzyme and pathway engineering IP for small-molecule and biological manufacturing, though Codexis is more established and broader in scope.

Emerging players

  • Compass Pathways: Clinical-stage mental health company developing psilocybin therapy for treatment-resistant depression. Comparable end-market focus on psychedelic-derived mental-health therapeutics; differs in using chemical synthesis rather than biosynthesis for its COMP360 psilocybin.

Others

  • ATAI Life Sciences: Clinical-stage biopharma platform developing psychedelic and mental-health therapeutics. Listed in CBT's materials as a joint venture partner on TryptageniX (ATAI relationship) and represents both a comparable psychedelic therapeutics peer and a financial/strategic partner.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

CB Therapeutics social profiles

Digital presence

CB Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

CB Therapeutics leadership team

Management profile

Number of profiles

Profiles14 records

CB Therapeutics funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

CB Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CB Therapeutics

What does CB Therapeutics do?

CB Therapeutics operates a precision fermentation platform that uses engineered yeast strains to biosynthetically produce over 100 rare compounds across eight classes, including phytocannabinoids (CBD, CBG, CBC, CBN, THCV), tryptamines (psilocybin, DMT, baeocystin, 5-HTP), rare alkaloids (mitragynine, stemmadenine acetate, catharanthine, tabersonine, salvinorin A), terpenes, ergolines, peptides, and designed analogs. The company supplies research-grade and pharmaceutical-grade compounds to pharmaceutical, biotech, research, wellness, and food-tech customers through direct B2B partnerships, research collaborations, and licensing agreements, with four branded programs—TryptageniX, TryptageniX AI, Aevora, and Korvane—covering mental health, AI-guided biological design, healthspan peptides, and non-opioid pain research.

Is CB Therapeutics a public or private company?

CB Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was CB Therapeutics founded?

CB Therapeutics was founded in 2018. It employs 11 to 50 people.

Where is CB Therapeutics based?

CB Therapeutics is headquartered in Carlsbad, United States, in the North America region.

How does CB Therapeutics make money?

Three revenue lines are on record. Biosynthetic Compound Sales are the primary driver. The others are research Collaborations & Licensing and platform Technology Access.

Who are CB Therapeutics's main competitors?

Direct peers on record are Ginkgo Bioworks, Amyris, Conagen, Checkerspot, Lumen Bioscience, Pivot Bio and Ingenza. Codexis is listed as a broad incumbent. Compass Pathways is listed as an emerging player. ATAI Life Sciences is listed as an others.

Does CB Therapeutics have an API?

No public API is recorded for CB Therapeutics.

What industry is CB Therapeutics in?

CB Therapeutics's product category is Biopharmaceutical Manufacturing. Its primary akta.pro industry code is CRADAGAD, Herbal & Botanical Supplements, with a secondary code of HLAIADAG, Sleep, Stress & Mood Support. Its NAICS code is 325411 and its SIC code is 2833.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EIN PresswireCB Therapeutics: After the Executive Order, Supply Becomes the Binding Constraint on Psychedelic MedicineCB Therapeutics is opening its biosynthesis platform to new research and commercial partners after the April 2026 Executive Order on Psychedelic Medicines. The company's yeast-engineered strains produce strictosidine for monoterpene indole alkaloids, addressing supply constraints for psychedelic compounds. It is engaging with clinical-stage developers across its active programs.NewsfileCB Therapeutics Introduces Sustainable Retinol ProductionCB Therapeutics has unveiled a new method for producing Retinol through precision fermentation, which aims to make the process faster, cleaner, and more environmentally friendly. The company emphasizes that this sustainable approach can cater to the growing global demand for eco-friendly skincare solutions. CB Therapeutics, founded on years of research, is looking to collaborate with other companies in the clean beauty sector to innovate further.NewsfileCB Therapeutics Unveils Revolutionary Breakthroughs in Crafting Pharmaceutical-Grade Cannabinoids and AnaloguesCB Therapeutics announced advancements in the production of pharmaceutical-grade cannabinoids using precision fermentation technology, which aims to transform the pharmaceutical industry. This method promises to provide consistent, high-quality cannabinoids while minimizing environmental impact compared to traditional cultivation practices. The company seeks to collaborate with pharmaceutical and biotech partners to enhance cannabinoid-based therapeutics.YahooCB Therapeutics Breaks Ground on Sustainable Ergoline Biosynthesis Through Precision FermentationCB Therapeutics announced an expansion of its precision fermentation platform to produce ergoline-based compounds, which are structurally related to alkaloids from ergot fungi. The company aims to offer a sustainable, scalable pathway for these molecules, which have potential in neurological research, psychiatric applications, and treatments for migraines, postpartum hemorrhage, and Parkinson's disease.SynBioBetaEnabling Psychedelics Research with Precision FermentationPsylink and CB Therapeutics are utilizing precision fermentation to produce psychedelics like psilocybin in engineered yeast, aiming to overcome the low yields and sustainability issues associated with mushroom extraction. This synthetic biology approach enables consistent quality, scalable production, and the development of patentable psychedelic derivatives for treating mental health disorders.MyJoyOnlineSouthern California Based-CB Therapeutics develops eco-conscious solutions through precision fermentationCB Therapeutics, a Southern California-based company, has developed eco-friendly solutions through precision fermentation for sustainable food and active ingredient manufacturing. The firm has created various food tech prototypes with low-cost and environmentally sustainable methods while actively seeking partnerships for scalable manufacturing. The company has made significant advancements in producing animal-free proteins and improving product nutritional content and quality.Crunchbase NewsPsychedelics Provide New Frontier For Venture Funding, But Nuances PrevailVenture capital investment in psychedelics-related startups surged to over $236 million between July 2021 and July 2022, reflecting growing legitimacy for psychedelic therapeutics amid regulatory shifts. Major players Compass Pathways and MindMed have raised significant funding to develop FDA-approved treatments for mental health conditions, while new firms like CB Therapeutics and Delix Therapeutics focus on novel drug production and non-hallucinogenic compounds. The sector faces complex ethical and legal challenges regarding patenting natural substances and the tension between commercialization and decriminalization efforts.EsgnewsCB Therapeutics granted a new patent that will help further provide eco-conscious avenues for psychedelic researchCB Therapeutics has been granted a new patent for using microorganisms to produce tryptamines, including psilocybin, enhancing eco-conscious avenues for psychedelic research. This patent enables the company to own a sustainable production process aimed at the growing psychedelic medicine industry, positioning them as an innovative player focused on environmental sustainability. The firm aims to facilitate partnerships that can diversify service offerings within the psychedelic space through collaboration.GlobeNewswireCB Therapeutics granted a new patent that will help further provide eco-conscious avenues for psychedelic researchCB Therapeutics was granted a patent for using microorganisms to produce tryptamines and analogs like psilocybin. The patent covers a precision fermentation process that is scalable and eco-conscious, contrasting with costly or waste-heavy methods. The company aims to standardize sustainable psychedelic research and support partnerships.San Diego Business JournalCB Therapeutics on the MoveCB Therapeutics moved into a new 16,000-square-foot corporate headquarters in Carlsbad after outgrowing its previous leased space. The facility includes research labs and GMP manufacturing capabilities to support the company's growth in producing molecules for drug candidates and food alternatives. The company projects revenue between $3.5 million and $7 million for 2022.